Proteins and Peptides

09 Nov 2019 Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
09 Nov 2019 Codiak Presents New Preclinical Data for First-in-Class Exosome Therapeutic Candidates, exoIL-12 and exoSTING, Demonstrating Potent Anti-Tumor Activity
08 Nov 2019 Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
07 Nov 2019 Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
06 Nov 2019 BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients
05 Nov 2019 Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
05 Nov 2019 Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)
04 Nov 2019 Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint
01 Nov 2019 Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome
31 Oct 2019 Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
31 Oct 2019 ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
30 Oct 2019 TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction
28 Oct 2019 Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)
28 Oct 2019 IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
26 Oct 2019 VISEN Pharmaceuticals announces China Phase 3 clinical study initiation for TransCon human growth hormone, the first unmodified long-acting growth hormone in China
25 Oct 2019 Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS
25 Oct 2019 FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
21 Oct 2019 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
17 Oct 2019 Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
16 Oct 2019 Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
16 Oct 2019 Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
16 Oct 2019 Aro Biotherapeutics Debuts Lead Centyrin Candidate at 2019 OTS Meeting
15 Oct 2019 AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
14 Oct 2019 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
12 Oct 2019 Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up